ImageneBio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	0.8	3.5	7.96
Revenue Growth (YoY)	-89.95%	-56.04%	-
Gross Profit	0.8	3.5	7.96
Selling, General & Admin	17.88	8.39	7.96
Research & Development	29.01	32.11	21.93
Operating Expenses	46.89	40.5	29.89
Operating Income	-46.09	-37	-21.93
Interest & Investment Income	0.03	0.37	1.19
Other Non Operating Income (Expenses)	3.15	0.07	-0.14
Pretax Income	-43.31	-36.56	-20.87
Income Tax Expense	-0.06	0.01	0.28
Net Income	-43.25	-36.57	-21.15
Preferred Dividends & Other Adjustments	10.11	11.82	10.89
Net Income to Common	-53.36	-48.38	-32.04
Shares Outstanding (Basic)	393	391	321
Shares Outstanding (Diluted)	393	391	321
Shares Change (YoY)	22.60%	21.97%	-
EPS (Basic)	-0.14	-0.12	-0.10
EPS (Diluted)	-0.14	-0.12	-0.10
Free Cash Flow	-44.1	-21.32	-18.54
Free Cash Flow Per Share	-0.11	-0.05	-0.06
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-5761.13%	-1057.14%	-275.37%
Profit Margin	-6669.75%	-1382.40%	-402.39%
Free Cash Flow Margin	-5512.63%	-609.11%	-232.83%
EBITDA	-46.07	-35.86	-19.52
EBITDA Margin	-	-	-245.15%
D&A For EBITDA	0.02	1.14	2.41
EBIT	-46.09	-37	-21.93
EBIT Margin	-	-	-275.37%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q